IPO Boutique

Fate Therapeutics, Inc. IPO Advisory

Share this IPO Profile:

Smart Search
Company begins with...
Company contains...

For IPO Boutique's "scale of 1 to 5" BUY rating on Fate Therapeutics, Inc., and our comprehensive analysis, click "Buy Market Research".
Company
Symbol
Price Range
Issue Price
Open
Shares
Trade Date
Fate Therapeutics, Inc.FATE -
NASDAQ
$6.00-$8.00 $6.00 $6.566.7 million10/1/2013
Cowen & Co., BMO Capital Markets
Co-Manager(s):
Wedbush PacGrow Life Sciences
Health Care
Filing(s):

Filed 2013-08-13



Fate Therapeutics, Inc. Quote & Chart - Click for current quote - FATE

About Fate Therapeutics, Inc. (adapted from Fate Therapeutics, Inc. prospectus):
They are a clinical-stage biopharmaceutical company engaged in the discovery and development of pharmacologic modulators of adult stem cells to treat orphan diseases, including certain hematologic malignancies, lysosomal storage disorders and muscular dystrophies.

This description is adapted from prospectus. This description is not intended to be a recommendation to buy stock from this company. To see the company's full description, view their prospectus.



IPO Boutique aggregates information on public companies and private companies, such as "FATE" IPO, which is intended to educate our readers and help them evaluate potential investment opportunities and market conditions. We endeavor to research the financial industry and obtain independent verification of factual statements before presenting them to our users. Be informed.

Used our Comprehensive Single Promo Advisory and want more?
We also offer a monthly or annual subscription






© 2005 - 2024 IPO Boutique. All Rights Reserved